We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

Back to rankings

3 hedge funds and large institutions have $0 invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% less funds holding

Funds holding: 65 → 3 (-62)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $95.3M → $0 (-$95.3M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 59

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-62
Holders Change %
-95.38%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
59
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$37.3M
2
DA
DSC Advisors
Illinois
-$11.2M
3
O
OrbiMed
New York
-$8.59M
4
MP
Mangrove Partners
Connecticut
-$5.93M
5
Morgan Stanley
Morgan Stanley
New York
-$4.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
– -$37.3M -11,203,881 Closed
DA
2
DSC Advisors
Illinois
– -$11.2M -3,365,000 Closed
O
3
OrbiMed
New York
– -$8.59M -2,577,982 Closed
MP
4
Mangrove Partners
Connecticut
– -$5.93M -1,779,448 Closed
Morgan Stanley
5
Morgan Stanley
New York
– -$4.69M -1,407,948 Closed
Axa
6
Axa
France
– -$4.34M -1,304,424 Closed
SI
7
Sofinnova Investments
California
– -$3.87M -1,162,176 Closed
PHP
8
Parkman Healthcare Partners
Connecticut
– -$3.1M -932,141 Closed
BlackRock
9
BlackRock
New York
– -$1.88M -564,004 Closed
SM
10
Senvest Management
New York
– -$1.69M -506,214 Closed
DMK
11
David M. Knott
– -$1.27M -381,146 Closed
6CM
12
683 Capital Management
New York
– -$1.25M -375,100 Closed
HVC
13
Healthcare Value Capital
New Jersey
– -$1.17M -350,000 Closed
TCM
14
Tekla Capital Management
Massachusetts
– -$1M -300,781 Closed
First Manhattan
15
First Manhattan
New York
– -$771K -231,800 Closed
Baillie Gifford & Co
16
Baillie Gifford & Co
United Kingdom
– -$730K -219,400 Closed
JGC
17
J. Goldman & Co
New York
– -$562K -168,778 Closed
CL
18
CSS LLC
Illinois
– -$471K -141,187 Closed
Wells Fargo
19
Wells Fargo
California
– -$452K -135,701 Closed
MA
20
MYDA Advisors
New York
– -$390K -117,254 Closed
EMG
21
ETF Managers Group
New Jersey
– -$374K -114,087 Closed
AIM
22
ARK Investment Management
Florida
– -$367K -110,343 Closed
Bank of America
23
Bank of America
North Carolina
– -$349K -104,927 Closed
Goldman Sachs
24
Goldman Sachs
New York
– -$277K -83,119 Closed
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
– -$248K -74,496 Closed
1
2 3

FOMX Hedge Fund Activity: Q1 2020 in Review

3 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q1 2020, worth a combined $0 — down 100% from $95.3M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of FOMX and 0 opened new positions — a net loss of 59 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Perceptive Advisors, exiting entirely with an estimated $37.3M sold.

  • 3 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q1 2020, down from 65 in Q4 2019.
  • Funds reported $0 of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q1 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q1 2020 and 59 closed out, a net change of -59 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q1 2020 was Perceptive Advisors, an estimated $37.3M sold.

Based on aggregated 13F filings for Q1 2020.